hydrochlorothiazide has been researched along with Cognitive Dysfunction in 1 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
Cognitive Dysfunction: Diminished or impaired mental and/or intellectual function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess whether long-term treatment with candesartan/hydrochlorothiazide, rosuvastatin, or their combination can slow cognitive decline in older people at intermediate cardiovascular risk." | 3.91 | Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study. ( Avezum, A; Bosch, J; Dagenais, G; Dans, A; Diaz, R; Hart, R; Held, C; Keltai, M; Khunti, K; Lee, SF; Leiter, LA; Lewis, BS; Lonn, EM; O'Donnell, M; Pogue, JM; Reid, C; Sharma, M; Sliwa, K; Swaminathan, B; Toff, WD; Yusuf, S, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bosch, J | 1 |
| O'Donnell, M | 1 |
| Swaminathan, B | 1 |
| Lonn, EM | 1 |
| Sharma, M | 1 |
| Dagenais, G | 1 |
| Diaz, R | 1 |
| Khunti, K | 1 |
| Lewis, BS | 1 |
| Avezum, A | 1 |
| Held, C | 1 |
| Keltai, M | 1 |
| Reid, C | 1 |
| Toff, WD | 1 |
| Dans, A | 1 |
| Leiter, LA | 1 |
| Sliwa, K | 1 |
| Lee, SF | 1 |
| Pogue, JM | 1 |
| Hart, R | 1 |
| Yusuf, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Heart Outcomes Prevention Evaluation-3[NCT00468923] | Phase 4 | 12,705 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for hydrochlorothiazide and Cognitive Dysfunction
| Article | Year |
|---|---|
Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cognition; Cognitive Dysfunction; | 2019 |